Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02715531 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 243
- Enrollment target
NCT02715531: Completed Phase 1 study, sponsored by Hoffmann-La Roche.
NCT02715531 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 243 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (305% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02715531, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 243 participants
- Enrollment target
Study Summary
This study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab in combination with bevacizumab, bevacizumab + oxaliplatin, leucovorin and 5-fluorouracil (5-FU) (FOLFOX), vanucizumab, nab-paclitaxel + gemcitabine, FOLFOX, or 5-FU + cisplatin, in participants with solid tumors.
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- DRUG Leucovorin
- DRUG Gemcitabine
- DRUG 5-FU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2016-04-06 |
| Est. Completion | 2021-05-31 |
| Phase | Phase 1 |
What the finished NCT02715531 record still lists
NCT02715531 is an interventional study that assigns participants to a tested intervention. The registered 243 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (305% higher).
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT02715531 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02715531 about?
NCT02715531 is a clinical study titled "A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors". This study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab in combination with bevacizumab, bevacizumab + oxaliplatin, leucovorin and 5-fluorouracil (5-FU) (FOLFOX), vanucizumab, nab-paclitaxel + gemcitabine, FOLFOX, or 5-FU + cisplatin, in participants with solid tumors.
What is the current status of trial NCT02715531?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 243 participants. The study started on 2016-04-06. Estimated completion is 2021-05-31.
What interventions are being tested in trial NCT02715531?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Leucovorin (DRUG), Gemcitabine (DRUG), 5-FU (DRUG).
Who is sponsoring clinical trial NCT02715531?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02715531's enrollment target sits among peer trials
243 193rd of 2000 higher than 1,807 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06253871 · 243 participants · Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
- NCT06289491 · 243 participants · NA
A Trial of Hydrus Microstent Versus Goniotomy
- NCT06536296 · 243 participants · NA
The Impact of Music Medicine on Preterm Brain Development and Behavior
- NCT06907615 · 243 participants · Phase 2
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI